Telix Pharmaceuticals Ltd ADR(TLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 5:27 AM ET (Korea 9/15 18:27)
Full metrics table
| Index | - | P/E | 125.99 | EPS (ttm) | 0.09 | Insider Own | - | Shs Outstand | 334.1M | Perf Week | -1.34% |
| Market Cap | 4.00B | Forward P/E | 257.71 | EPS next Y | -40.94% | Insider Trans | - | Shs Float | - | Perf Month | -4.46% |
| Enterprise Value | 4.33B | PEG | - | EPS next Q | 0 | Inst Own | 0.94% | Short Float | - | Perf Quarter | 23.22% |
| Income | 0.03B | P/S | 4.48 | EPS this Y | 466.82% | Inst Trans | -0.53% | Short Ratio | 1.54 | Perf Half Y | 50.06% |
| Sales | 0.89B | P/B | 8.21 | EPS next 5Y | - | ROA | 2.63% | Short Interest | 0.26M | Perf YTD | 57.28% |
| Book/sh | 1.44 | P/C | 15.89 | EPS past 3/5Y | 55.05% 29.38% | ROE | 7.39% | 52W High | -5.61% ($12.48) | Perf Year | 27.9% |
| Cash/sh | 0.74 | P/FCF | - | Sales past 3/5Y | 93.54% 195.21% | ROIC | 3.2% | 52W Low | 87.58% ($6.28) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 142.08 | EPS Y/Y TTM | 198.49% | Gross Margin | 52.13% | Volatility(W/M) | 3.73% 2.39% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 4.85 | Sales Y/Y TTM | 33.78% | Oper. Margin | -0.81% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | EPS Q/Q | - | Profit Margin | 3.76% | RSI (14) | 53.18 | Recom | 1.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.01 | Sales Q/Q | - | SMA20 | 1.11% ($11.65) | Beta | -0.18 | Target Price | $18.11 |
| Payout | - | Debt/Eq | 1.19 | Earnings | 2026/8/19 | SMA50 | 4.91% ($11.23) | Rel Volume | 3.66 | Prev Close | $11.29 |
| Employees | 1184 | LT Debt/Eq | 1.16 | EPS/Sales Surpr. | 140.27% -0.55% | SMA200 | 23.84% ($9.51) | Avg Volume(3M) | 0.17M | Price | $11.78 |
| IPO | 2024/11/14 | Option/Short | No/Yes | Trades | 5461 | Volume | 630,490 | Change | 4.34% |
Company
TLX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
☢️ This is an Australia-based biopharmaceutical company that develops and sells radiopharmaceuticals. It commercializes and sells radiopharmaceuticals for cancer diagnostics, including prostate cancer, and develops radiopharmaceuticals for cancer treatment, giving it exposure to demand for radiopharmaceuticals. The company operates in the radiopharmaceutical sector.
Over the past 1 year, on the higher side
6% below its 1-year high.
TLX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +466.8% this year.
Tap to view numbers
The price looks about right
Trading at 126.0 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 0.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FLAU 0.00%
ISCF 0.00%
SCZ 0.00%
IPAC 0.00%
WSML 0.00%It ranks #4 in the industry
Based on market cap of $4B.
TLX $4B PER 126.0
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is TLX?
TLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TLX?
The market cap of TLX is approximately $4.0B, ranking 1,560 within its sector.
What is the P/E ratio of TLX?
TLX has a P/E ratio of approximately 126.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TLX?
TLX has recorded a 52-week high of $12.48 and a low of $6.28.
